NDP11033 and SirReal2 also reduced PANC-1 cell viability, suggesting that targeted Sirt2 inhibition via the ‘selectivity pocket’ (Figure 2) may be beneficial in pancreatic cancer [125]. Here, SIRT2 is linked to familial pancreatic carcinoma.